Skip to main content
Ninth Circuit· 8/18/2017

Levi v. Atossa Genetics, Inc.

Citations

  • 868 F.3d 784
  • 2017 WL 3568088
  • 2017 U.S. App. LEXIS 15658

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

  • holding that an “opinion statement did 12 not fairly align[] with the information in [the CEO’s] possession at the time” so it was “misleading 13 by omission”
  • finding that plaintiff pled falsity where defendants said a drug had “gone through all of the FDA clearance process,” but it had not received FDA clearance
  • finding statement that management was “reasonably confident” in FDA communications to be nonactionable puffery
  • “to satisfy materiality, ‘there must be a 4 substantial likelihood that the disclosure of the omitted fact would have been viewed by the 5 reasonable investor as having significantly altered the ‘total mix’ of information made 6 available’”
  • “historical 8 stock prices are not subject to reasonable dispute”

Source: CourtListener parenthetical corpus (CC0).

Judges: Gould, Paez, Ivan, Lemelle

Read full opinion on CourtListener

Cited by

5 cases in this archive cite this case.

Cites

22 cases in this archive are cited by this case; the 20 most cited are listed.

Sourced from CourtListener / Free Law Project (CC0).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.